136 related articles for article (PubMed ID: 20056801)
1. Antipsychotic polypharmacy in outpatients at Birch Hill Hospital: incidence and adherence to guidelines.
Ranceva N; Ashraf W; Odelola D
J Clin Pharmacol; 2010 Jun; 50(6):699-704. PubMed ID: 20056801
[TBL] [Abstract][Full Text] [Related]
2. National trends in psychotropic medication polypharmacy in office-based psychiatry.
Mojtabai R; Olfson M
Arch Gen Psychiatry; 2010 Jan; 67(1):26-36. PubMed ID: 20048220
[TBL] [Abstract][Full Text] [Related]
3. The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards - a cluster randomized controlled trial.
Thompson A; Sullivan SA; Barley M; Strange SO; Moore L; Rogers P; Sipos A; Harrison G
Psychol Med; 2008 May; 38(5):705-15. PubMed ID: 17825122
[TBL] [Abstract][Full Text] [Related]
4. Explicit versus implicit review to explore combination antipsychotic prescribing.
Wheeler A
J Eval Clin Pract; 2009 Aug; 15(4):685-91. PubMed ID: 19674220
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications.
Aggarwal NK; Sernyak MJ; Rosenheck RA
J Clin Psychopharmacol; 2012 Jun; 32(3):323-8. PubMed ID: 22544006
[TBL] [Abstract][Full Text] [Related]
6. Associations between adherence to guidelines for antipsychotic dose and health status, side effects, and patient care experiences.
Dickey B; Normand SL; Eisen S; Hermann R; Cleary P; Cortés D; Ware N
Med Care; 2006 Sep; 44(9):827-34. PubMed ID: 16932134
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic polypharmacy at the University Psychiatric Hospital in Serbia.
Divac N; Jasović-Gasić M; Samardzić R; Lacković M; Prostran M
Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1250-1. PubMed ID: 17960865
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
9. Prescribing patterns and predictors of high-level polypharmacy in the elderly population: A prospective surveillance study from two teaching hospitals in India.
Harugeri A; Joseph J; Parthasarathi G; Ramesh M; Guido S
Am J Geriatr Pharmacother; 2010 Jun; 8(3):271-80. PubMed ID: 20624616
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with antipsychotic dosing in psychiatric inpatients: a prospective study.
Barbui C; Biancosino B; Esposito E; Marmai L; Donà S; Grassi L
Int Clin Psychopharmacol; 2007 Jul; 22(4):221-5. PubMed ID: 17519645
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison.
Roh D; Chang JG; Kim CH; Cho HS; An SK; Jung YC
Aust N Z J Psychiatry; 2014 Jan; 48(1):52-60. PubMed ID: 23671214
[TBL] [Abstract][Full Text] [Related]
12. Clinicians' reasons for deviations from recommended dosing practices for antipsychotic medications.
Sernyak MJ; Rosenheck R
Adm Policy Ment Health; 2007 Nov; 34(6):540-7. PubMed ID: 17957463
[TBL] [Abstract][Full Text] [Related]
13. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
Wheeler AJ
Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
[TBL] [Abstract][Full Text] [Related]
14. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
[TBL] [Abstract][Full Text] [Related]
15. [The trend for megadose polypharmacy in antipsychotic pharmacotherapy: a prescription survey conducted by the psychiatric clinical pharmacy research group].
Yoshio T
Seishin Shinkeigaku Zasshi; 2012; 114(6):690-5. PubMed ID: 22844820
[TBL] [Abstract][Full Text] [Related]
16. Patterns and frequency of atypical antipsychotic prescribing in psychiatric medical centers: a cross-sectional national survey.
Diatta T; Blazejewski S; Portier A; Lignot S; Quesnot A; Moore N; Fourrier-Réglat A
Fundam Clin Pharmacol; 2007 Aug; 21(4):371-8. PubMed ID: 17635175
[TBL] [Abstract][Full Text] [Related]
17. Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia.
Hazra M; Uchida H; Sproule B; Remington G; Suzuki T; Mamo DC
Psychiatry Clin Neurosci; 2011 Dec; 65(7):676-8. PubMed ID: 22176287
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological management of acute mania: does current prescribing practice reflect treatment guidelines?
Streeruwitz A; Barnes TR; Fehler J; Ohlsen R; Curtis VA
J Psychopharmacol; 2007 Mar; 21(2):206-9. PubMed ID: 17329301
[TBL] [Abstract][Full Text] [Related]
19. Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy.
Santone G; Bellantuono C; Rucci P; Picardi A; Preti A; de Girolamo G
Pharmacoepidemiol Drug Saf; 2011 May; 20(5):441-9. PubMed ID: 21523847
[TBL] [Abstract][Full Text] [Related]
20. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia.
Xiang YT; Weng YZ; Leung CM; Tang WK; Ungvari GS
Pharmacopsychiatry; 2007 Mar; 40(2):47-52. PubMed ID: 17447172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
